Use of oral VP16-213 as primary chemotherapeutic agent in treatment of gestational trophoblastic disease
- 1 December 1984
- journal article
- research article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 150 (8) , 924-927
- https://doi.org/10.1016/0002-9378(84)90382-x
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- The role of VP16-213 (Etoposide; NSC-141540) in gestational choriocarcinomaCancer Chemotherapy and Pharmacology, 1982
- Anti-tumour activity of the epipodophyllin derivative VP16–213 (etoposide: NSC-141540) in gestational choriocarcinomaPublished by Elsevier ,1980
- METHOTREXATE WITH CITROVORUM FACTOR RESCUE FOR GESTATIONAL TROPHOBLASTIC NEOPLASMS1978
- CHORIOCARCINOMA - CAN WE AFFORD TO CURE CANCER1978
- EPEG, a new antineoplastic epipodophyllotoxinClinical Pharmacology & Therapeutics, 1975
- Treatment of gestational trophoblastic diseaseAmerican Journal of Obstetrics and Gynecology, 1974
- Treatment of metastatic trophoblastic disease: Good and poor prognosisAmerican Journal of Obstetrics and Gynecology, 1973